Literature DB >> 6404816

Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

S J Cryz, E Fürer, R Germanier.   

Abstract

A simple, reproducible model of fatal Pseudomonas aeruginosa sepsis in mice during immunosuppression was developed. Mice were rendered leukopenic (less than or equal to 800 leukocytes per mm3 of blood) for a period of 5 days by multiple injections of cyclophosphamide. Mice were challenged at the onset of leukopenia by instilling the bacteria onto a 0.5-mm incision made into the back. The mean lethal dose (LD50) for P. aeruginosa PA220 and M-2 was less than 20 bacteria. The mean time to death for these strains ranged from 46 to 59 h. Leukopenic mice were comparatively resistant when challenged with Klebsiella pneumoniae (LD50 = 1.5 x 10(6)) or Staphylococcus aureus (LD50 greater than 10(6)). Infection with P. aeruginosa was characterized by rapid bacterial multiplication in the skin at the site of infection, producing ecthyma gangrenosum. Bacteremia and colonization of the liver were pronounced 21 h postinfection. This model should prove to be a useful tool for studying the pathogenesis of P. aeruginosa infections under immunosuppressed conditions.

Entities:  

Mesh:

Year:  1983        PMID: 6404816      PMCID: PMC348064          DOI: 10.1128/iai.39.3.1067-1071.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Pseudomonas eye infections in cyclophosphamide-treated mice.

Authors:  L D Hazlett; D D Rosen; R S Berk
Journal:  Invest Ophthalmol Vis Sci       Date:  1977-07       Impact factor: 4.799

2.  Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia.

Authors:  M Haghbin; D Armstrong; M L Murphy
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

3.  Pseudomonas aeruginosa vaccine in cancer patients.

Authors:  L S Young; R D Meyer; D Armstrong
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

4.  Experimental infections with protease-deficient mutants of Pseudomonas aeruginosa in mice.

Authors:  B Wretlind; T Kronevi
Journal:  J Med Microbiol       Date:  1978-05       Impact factor: 2.472

5.  Influence of iron on yields of extracellular products in Pseudomonas aeruginosa cultures.

Authors:  M J Bjorn; P A Sokol; B H Iglewski
Journal:  J Bacteriol       Date:  1979-04       Impact factor: 3.490

6.  Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonas infection in neutropenia.

Authors:  E J Ziegler; H Douglas
Journal:  J Infect Dis       Date:  1979-03       Impact factor: 5.226

7.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.

Authors:  G B Pier; H F Sidberry; J C Sadoff
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

8.  Passive immunity against pseudomonas sepsis during granulocytopenia.

Authors:  L Harvath; B R Andersen; H J Amirault
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

9.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies.

Authors:  I A Holder; R Wheeler; T C Montie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

10.  Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa.

Authors:  K Snell; I A Holder; S A Leppla; C B Saelinger
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

View more
  25 in total

1.  Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

Authors:  Caroline Westwater; Laura M Kasman; David A Schofield; Phillip A Werner; Joseph W Dolan; Michael G Schmidt; James S Norris
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sigmaE).

Authors:  H Yu; J C Boucher; N S Hibler; V Deretic
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Cooperation between LepA and PlcH contributes to the in vivo virulence and growth of Pseudomonas aeruginosa in mice.

Authors:  Yutaka Kida; Takashi Shimizu; Koichi Kuwano
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

4.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

5.  Role of ornibactin biosynthesis in the virulence of Burkholderia cepacia: characterization of pvdA, the gene encoding L-ornithine N(5)-oxygenase.

Authors:  P A Sokol; P Darling; D E Woods; E Mahenthiralingam; C Kooi
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Authors:  T R Anderson; T C Montie
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

Review 7.  Organ Failure Due to Systemic Injury in Acute Pancreatitis.

Authors:  Pramod K Garg; Vijay P Singh
Journal:  Gastroenterology       Date:  2019-02-12       Impact factor: 22.682

8.  T lymphocyte-mediated protection against Pseudomonas aeruginosa infection in granulocytopenic mice.

Authors:  W G Powderly; G B Pier; R B Markham
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

9.  Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

10.  Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.

Authors:  P H Chandrasekar; J A Sluchak; J A Kruse
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.